Prescription medication · Dopamine Agonist (Prolactin)

cabergoline

Also sold as Dostinex. Cabergoline treats hyperprolactinemia.

Data updated 2026-05-15

4,670
FDA reportsLightly reported
2
InteractionsFew interactions
$1.32
Generic price (NADAC)

What the data shows

cabergoline (Dostinex) is a prescription Dopamine Agonist (Prolactin), among the least-reported drugs the FDA tracks (4,670 FDA reports), with 2 documented drug interactions.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

cabergoline (Dostinex) is a prescription Dopamine Agonist (Prolactin). Cabergoline treats hyperprolactinemia.

Cabergoline is a medicine that helps lower the amount of prolactin in your body. Prolactin is a hormone.

Drug Pricing (NADAC)

Generic Price

$1.32/unit

Generic Available

Yes (5 manufacturers)

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

Compare with Another Drug → Full Side Effects Report →

What it does

Cabergoline treats hyperprolactinemia.

Common side effects

Nausea, Headache, Dizziness

Key warnings

You should not take cabergoline if you have uncontrolled high blood pressure.

The sections below are summarized in plain English from cabergoline's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Cabergoline works by acting like dopamine in your brain. Dopamine is a chemical that helps control prolactin release. By mimicking dopamine, cabergoline lowers prolactin levels.

Side Effects (from patient reports)

Based on 4,670 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for cabergoline, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for cabergoline each year to the FDA Adverse Event Reporting System (FAERS).

0100200300400 20042007201020132016201920222025 293

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where cabergoline sits

cabergoline has more FDA adverse-event reports than 24% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is cabergoline; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 4,670 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.

Total Reports

4,670

Reports Mentioning Death

245

5.2% of reports — not proof of cause

Hospitalization Reports

1,549

Top Indication

Product Used For Unknown Indication

Gender Distribution

Female 2,447 (59%)
Male 1,693 (41%)

Age Distribution

0–17 79
18–44 1,209
45–64 1,090
65–74 559
75+ 303

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
3 HEADACHE 319
4 FATIGUE 275
5 NAUSEA 274
6 DIZZINESS 224
7 MALAISE 209
8 PAIN 195
9 DIARRHOEA 175
10 CONDITION AGGRAVATED 170
11 ANXIETY 158
12 RASH 155
13 VOMITING 154
15 FALL 150
16 ABDOMINAL DISCOMFORT 148
17 DRUG INTERACTION 142
18 WEIGHT DECREASED 138

Reactions in Death Reports

LUNG NEOPLASM MALIGNANT 46
CONDITION AGGRAVATED 45
ARTHROPATHY 42
ABDOMINAL DISCOMFORT 41
DEATH 41
INFLAMMATION 41
LOWER RESPIRATORY TRACT INFECTION 41
RASH 41
COVID-19 40
PULMONARY PAIN 40

Reactions in Hospitalization Reports

DRUG ABUSE 111
RASH 110
ARTHROPATHY 103
FALL 102
LOWER RESPIRATORY TRACT INFECTION 98
PULMONARY PAIN 96
ABDOMINAL DISCOMFORT 95
INTENTIONAL PRODUCT MISUSE 95
OVERDOSE 92
HEADACHE 90

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

You should not take cabergoline if you have uncontrolled high blood pressure. Also, don't take it if you're allergic to ergot medicines. Before starting, your doctor should check your heart. Cabergoline is also not recommended if you have a history of heart valve disorders or fibrotic disorders.

Known Drug Interactions

Drug Interactions: Cabergoline should not be administered concurrently with D 2 -antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.

Mechanism: These drugs have opposite effects on the brain's dopamine system, so taking them together can stop them from working.

Alitretinoin (oral) Cabergoline Cannabinoids Cinacalcet Galantamine Ivacaftor Monitor for adverse reactions.

Mechanism: Itraconazole slows down how fast your body breaks down cabergoline. This can cause the level of cabergoline in your blood to rise.

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

Can I stop taking cabergoline on my own?
No, do not stop taking cabergoline without talking to your doctor first.
How long will I need to take cabergoline?
You may need to take cabergoline for a long time. Your doctor will monitor your prolactin levels.
Will cabergoline cure my condition?
Cabergoline helps manage your condition by lowering prolactin levels. It may not be a permanent cure.
Can I drink alcohol while taking cabergoline?
Talk to your doctor about drinking alcohol while taking cabergoline.
What should I do if I feel dizzy after taking cabergoline?
Stand up slowly to avoid dizziness. If dizziness persists, contact your doctor.
Does cabergoline interact with other medications?
Yes, cabergoline can interact with other medications. Tell your doctor about all the medicines you take.
Can cabergoline cause weight gain?
Weight changes are possible. Discuss any concerns with your doctor.
How often will I need blood tests?
Your doctor will order blood tests to monitor your prolactin levels regularly.
What if I want to get pregnant?
Talk to your doctor about your plans to get pregnant. They may adjust your dose.
Can I take cabergoline with food?
You can take cabergoline with or without food.
What are the common side effects of cabergoline?
The registry lists Nausea, Headache, Dizziness, Constipation, Tiredness among the most-reported FAERS reaction terms for cabergoline. The compiled record contains 4,670 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does cabergoline interact with other medications?
The registry has 2 documented interaction rows for cabergoline. Notable source-record pairings include metoclopramide, itraconazole. These rows are not a complete medication review.
What drug class is cabergoline?
cabergoline belongs to the Dopamine Agonist (Prolactin) drug class. It requires a prescription (Rx). Cabergoline treats hyperprolactinemia.
What pregnancy or breastfeeding source fields are listed for cabergoline?
The FDA label for cabergoline contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Other drugs grouped near cabergoline - same-class peers and common alternatives.

Compare cabergoline vs abiraterone side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for cabergoline: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on cabergoline

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for cabergoline

The FDA label for cabergoline (sold under brand names such as Dostinex) classifies it as a prescription-only medication in the Dopamine Agonist (Prolactin) class. Cabergoline treats hyperprolactinemia. Official labeling lists 5 commonly reported side effects, including Nausea, Headache, Dizziness.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 4,670 voluntary reports. The database also lists 2 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS shows a generic unit cost of $1.32.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: December 8, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page